Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis

MLA

Goluszko, E., et al. “Lymphotoxin-Alpha Deficiency Completely Protects C57BL/6 Mice from Developing Clinical Experimental Autoimmune Myasthenia Gravis.” Journal of Neuroimmunology, vol. 113, no. 1, Jan. 2001, pp. 109–18. EBSCOhost, https://doi.org/10.1016/S0165-5728(00)00420-3.

APA

Goluszko, E., Hjelmstrom, P., Deng, C., Poussin, M. A., Ruddle, N. H., & Christadoss, P. (2001). Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 113(1), 109–118. https://doi.org/10.1016/S0165-5728(00)00420-3

Chicago

Goluszko, E., P. Hjelmstrom, C. Deng, M. A. Poussin, N. H. Ruddle, and P. Christadoss. 2001. “Lymphotoxin-Alpha Deficiency Completely Protects C57BL/6 Mice from Developing Clinical Experimental Autoimmune Myasthenia Gravis.” Journal of Neuroimmunology 113 (1): 109–18. doi:10.1016/S0165-5728(00)00420-3.